| March, 2004 |
|
Incorporated as Oncolys BioPharma in Tokyo, Japan |
| May, 2004 |
|
First round of financing |
| August, 2004 |
|
Second round of financing |
| October, 2004 |
|
Third round of financing |
| December, 2004 |
|
New HQ established in Roppongi-2chome, Tokyo, Japan |
| March, 2005 |
|
Annual stockholders meeting |
| April 2005 |
|
Trade name "Telomelysin" registered |
| May 2005 |
|
Telomescan was adopted by NEDO's grant in 2005 titled, "Project for R&D on Molecule Imaging Equipment. R&D of Molecule Imaging Equipment for Malignant Tumor Therapy Support."
*NEDO: New Energy and Industrial Technology Development Organization |
| December 2005 |
|
Trade name "Oncolys" registered |
| February 2006 |
|
Fourth round of allocating new shares to a third party |
| March 2006 |
|
Filed an investigational new drug (IND) application for Telomelysin® with U.S. Food and Drug Administration (FDA) |
| March 2006 |
|
Fifth round of allocating shares to a third company |
| May 2006 |
|
Trade name "Telomescan" registered |
| June 2006 |
|
Concluded a joint development agreement with Sysmex Corporation to develop Telomescan® |
| June 2006 |
|
Concluded an exclusive license agreement with Yale University, US, granting Oncolys global exclusive license agreement of the novel anti-HIV agent, FESTINAVIR® |
| July 2006 |
|
Headquarters moved to 3-chome, Roppongi, Minato-ku, Tokyo |
| September 2006 |
|
Sixth round of financing |
| October 2006 |
|
Opened the Kyoto Research Center |
| October 2006 |
|
Seventh round of financing |
| October 2006 |
|
Obtained a patent for Telomelysin® in Japan (Patent No. 3867968) |
| October 2006 |
|
Initiated a phase I clinical trial with Telomelysin® in the US |
| September 2007 |
|
Award by Minister of Education, Culture, Sports, Science and Technology, "The 5th Japan Bio-Venture Award" |
| November 2007 |
|
Opened the Kobe Research Center |
| March 2008 |
|
Signed strategic alliance and license agreement with Medigen Biotechnology Corp. for Telomellysin® |
| March 2008 |
|
Signed strategic alliance and license agreement with Tacere Therapeutics, Inc. for OBP-701(TT-033) |
| March 2008 |
|
Eighth round of financing |
| March 2008 |
|
Filed an investigational new drug (IND) application for FESTINAVIR® Food and Drug Administration (FDA) |
| April 2008 |
|
Received IND approval from the US Food and Drug Administration (FDA)
for FESTINAVIR® to initiate phase-I clinical trial in the United States. |
